JAGUAR - Key Persons

Job Titles:

• Chief Financial Officer
• Member of the Executive Management Team

Ms. Lizak is an accomplished, high-performing finance, operations, and strategic executive with more than 25 years of leadership experience in private and public life science and technology companies. Prior to serving as Jaguar's CFO, she was the company's Chief Accounting Officer. Before joining Jaguar, she served in executive director and corporate controller roles at Zosano Pharma Corp.; Alexza Pharmaceuticals, Inc.; LaserCard Corporation; and subsidiaries of HID Global; and in other senior finance leadership roles in both private and public companies. Ms. Lizak holds an MBA from Pepperdine Graziadio Business School's Executive MBA program.

Job Titles:

• Chief Medical Officer
• Member of the Executive Management Team

Dr. Horton brings over 25 years of clinical research and development, medical affairs, senior executive, and consulting experience in the development of investigational and commercialized biopharmaceutical and drug-device combination products. She has extensive clinical development experience in multiple therapeutic areas, including cardiology, oncology, immunology, orthopedics, gastroenterology, women's health, and endocrinology. Prior to joining Napo Pharmaceuticals, she led clinical development and regulatory strategy as CMO at Coherus Biosciences, Itero Biopharmaceuticals, and SMC Biotechnology. As Head of Clinical and Medical Affairs at Scios, she led the clinical development program which ultimately drove the approval of Natrecor® and was on the senior executive team when Scios was acquired by Johnson & Johnson (JNJ) for $2.4B. At JNJ, with strategic marketing, she co-led the cardiovascular therapeutic area when JNJ in-licensed and began developing the blockbuster drug Xarelto®. She also served as CEO at Nile Therapeutics and TulangCo, Inc. Dr. Horton completed her Pediatric Cardiology fellowship and Pediatrics Residency at UCSF. She earned an MD and BS in Microbiology from the University of Florida.

Job Titles:

• Member of the Executive Management Team
• Scientist
• Chief Manufacturing Officer

Dr. Sesin is a pharmaceutical scientist with more than 30 years of experience, ranging from drug discovery through manufacturing. He is the developer of the crofelemer manufacturing process. Prior to serving as Jaguar's CMO, he was Director of Chemistry and QHSE at Bayer CropScience and Director of Chemistry at AgraQuest, Inc., and he spent nine years with Shaman Pharmaceuticals. Dr. Sesin holds a PhD from the University of Utah.

Job Titles:

• Member of the Board of Directors
• Founder and Managing Editor of EXXclaim Capital

Dr. Jayasuriya is the founder and managing editor of EXXclaim Capital, an early-stage venture fund focused on catalyzing innovation, entrepreneurship, and investment in women's health, and a co-founder of Evolvence India Life Science Fund (EILSF), the very first fund in India to focus exclusively on health care and invest in Indian pharmaceutical, biotechnology, medical device, and contract services companies. She has applied deep business, scientific, and medical knowledge in her career as a pharmaceutical company executive, private equity executive, and venture capitalist, providing her with a broad experience base spanning clinical, executive, entrepreneurial, and financial roles. In 2006, Dr. Jayasuriya co-founded EILSF, focusing exclusively on investment in Indian pharmaceutical, biotechnology, medical device, and contract services companies. Dr. Jayasuriya was previously a partner with Skyline Ventures in Palo Alto, and prior to that with the German/US venture capital firm TVM in San Francisco. Her prior positions include VP Business Development at Genomics Collaborative Inc.; Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation; and Director, Outcomes Research at Syntex Laboratories.

Job Titles:

• Chief Commercial Officer
• Member of the Executive Management Team

Mr. Wendt brings extensive experience in commercialization. Prior to joining Jaguar, he served at Gilead Sciences in a variety of field leadership and marketing roles in the HIV and hepatitis C therapeutic areas. Most recently, he led strategy and tactical development for a national team focused on policy and protocol development within key HIV treatment and prevention accounts, capacity building, and direct patient education. Mr. Wendt was also responsible for Gilead's efforts to increase hepatitis C virus screening and treatment among nonspecialist healthcare practitioners in support of Gilead's market development efforts for a $10 billion brand franchise. Before Gilead, Mr. Wendt was at Boehringer Ingelheim, where he led HIV and oncology sales teams across the US, and led commercial operations at Roxane Laboratories, which included sales operations, analytics, incentive compensation, and training. Mr. Wendt received his BS from Acadia University and an MBA from Dalhousie University in Nova Scotia.

Job Titles:

• Chairman of the Board of Directors
• Member of Our Board of Directors

Mr. Bochnowski has served as a member of our board of directors since February 2014 and as Chairman of our board since June 2014. In 1983, Mr. Bochnowski co-founded Technology Venture Investors after previously serving as CEO of two technology companies. Since 1988, Mr. Bochnowski has served as the founder and Managing Member of Delphi Ventures, a venture capital firm. Mr. Bochnowski holds an MBA from Harvard University Graduate School of Business and a BS in Aeronautics and Astronautics from Massachusetts Institute of Technology. We believe Mr. Bochnowski is qualified to serve on our board of directors due to his significant experience with venture capital-backed healthcare companies and experience as both an executive officer and member of the board of directors of numerous companies.

Job Titles:

• Member of the Board of Directors

From 2000 to 2010, Mr. Micek was managing director of Silicon Prairie Partners, LP, a Palo Alto, California-based family-owned venture fund. Since 2010, Mr. Micek has been managing partner of Verdant Ventures, a merchant bank dedicated to sourcing and funding university and corporate lab spinouts in areas including pharmaceuticals and cleantech. Mr. Micek serves on the board of directors of Armanino Foods of Distinction, Innovaro Corporation, and JAL/Universal Assurors. He is also a board member and the CEO and CFO of Enova Systems, and from March 2014 to August 2015 he served as interim CFO for Smith Electric Vehicles Inc. From 2000-2003, he was on the board of directors of Universal Warranty Corporation, a wholly owned subsidiary of GMACI (a General Motors subsidiary). Mr. Micek is a cum laude graduate of Santa Clara University, and the University of San Francisco School of Law, and is a practicing California attorney specializing in financial services. Additionally, he was an adjunct faculty professor in Corporate Governance and Ethics at the graduate school of Economics at the University of San Francisco in 2013 and 2014.

Job Titles:

• Member of the Board of Directors
• CEO of JBS Healthcare Ventures

Mr. Siegel has served as the CEO of JBS Healthcare Ventures since he founded the company in 2017. In June 2021, he also assumed the role of CEO and Chairman of the board of OPY Acquisition Corp. I, a public Nasdaq-listed company. From 2011 until 2017, he was a partner and healthcare sector head at Kingdon Capital Management. Prior to joining Kingdon, Mr. Siegel was a healthcare portfolio manager at SAC Capital Advisors from 2005 until 2011; an associate director of pharmaceutical and specialty pharmaceutical research at Bear, Stearns & Co.; a pharmaceuticals research associate at Dresdner Kleinwort Wasserstein; and a consultant in the Life Sciences Division of Computer Sciences Corporation. Mr. Siegel worked as a research associate at the Novartis Center for Immunobiology at Harvard Medical School and as a research assistant at Tufts University School of Medicine. He is also a director at Jaguar Health, Inc. and Sol-Gel Technologies Ltd, both Nasdaq-listed companies, and has served on the board of advisors of Vitalis LLC, a private pharmaceutical company, since March 2019. Previously he served on the Board of Directors of Lumara Health. Mr. Siegel received a BS in Psychology from Tufts University in 1995 and an MBA from Columbia Business School in 1999. We believe Mr. Siegel is qualified to serve on our board of directors due to his extensive knowledge of Mytesi®, his background in the pharmaceutical investment sector, and his previous board experience in this space.

Job Titles:

• Chief Compliance Officer
• Chief of Staff
• General Counsel
• Member of the Executive Management Team

Mr. Wolin joined Jaguar Health in November 2018. He brings more than 25 years of compliance, legal, and business experience with a number of life science, biotech, and healthcare companies. He has been part of leadership teams during three acquisitions, an IPO, and a turnaround. Prior to joining Jaguar Health, Mr. Wolin was the Chief Administrative Officer for Pacific Pulmonary Services. He is certified in Healthcare Compliance and Healthcare Privacy Compliance, enabling him to serve as the Chief Compliance Officer at public and private companies, including Natera, Inc.; Pacific Pulmonary Services; and Celera, Inc. Furthermore, Mr. Wolin was General Counsel for Berkeley HeartLab, Inc., and a healthcare partner at the Mintz Levin law firm in Washington, DC. Mr. Wolin completed his JD at the Catholic University of America, Columbus School of Law. He holds an MBA from the George Washington University School of Business and a BS in Accounting from the University of Maryland, College Park.

Job Titles:

• Member of the Executive Management Team
• Executive Vice President, Corporate & Business Development

Dr. Brunke brings to Jaguar over 30 years of scientific, operational, clinical, senior executive, and corporate development experience in both large and small biotechnology companies. Following her postdoctoral fellowship at the Institute for Cancer Research in Fox Chase, Dr. Brunke joined the seeds division of Sandoz, with her most recent position having been Research Director, overseeing a department whose successes included recombinant insect-resistant plants (GMOs) which have been an important backbone for the greater than $3 billion seed business of the now Syngenta Seeds. She was next part of the executive team that merged Mercator Genetics with Progenitor and helped take the resultant company public. Dr. Brunke was COO of Anexus Pharmaceuticals, a subsidiary of the Japanese public company MediBic, responsible for in- and out-licensing assistance for Japanese companies, and was next founding CEO of Cardeus Pharmaceuticals, a neuroscience company. In business and corporate development, Dr. Brunke has had primary responsibility for negotiating multiple partnerships and licenses, including with MedImmune and Astellas, and assisted in closing a deal with GlaxoSmithKline, among others. Dr. Brunke received her BA degree in Biochemistry, as well as PhD in Microbiology, from the University of Pennsylvania.

Job Titles:

• Chief Executive Officer
• Founder
• Member of the Board of Directors
• Member of the Executive Management Team
• President

Ms. Conte is the founder, president, and chief executive officer, and a member of the board of directors, of Jaguar Health, a commercial-stage pharmaceuticals company committed to discovering, developing, and commercializing plant-based prescription medicines for urgent global health needs. Mytesi®, the company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, is a first-in-class, plant-based anti-secretory agent and the first oral drug approved under FDA Botanical Guidance. In July 2017, two companies founded by Ms. Conte-Napo Pharmaceuticals, a human-focused pharmaceuticals company, and Jaguar Animal Health, the veterinary-focused licensor of all of Napo's technology-merged and now comprise Jaguar Health. In 1989, Ms. Conte also founded Shaman Pharmaceuticals, and has pioneered plant-based prescription medicine investigation and development for more than 30 years, including a recent Entheogen Therapeutics Initiative, looking at psychoactive plants for novel cures for mood disorders and CNS neurodegenerative diseases. Ms. Conte is a member of the board of directors of Healing Forest Conservatory, serves on the Editorial Advisory Board of Life Science Leader magazine, and serves on the Leadership Council of Pure Earth. She holds an MS in Physiology and Pharmacology from the University of California, San Diego, and an MBA and AB in Biochemistry from Dartmouth College.

Job Titles:

• Chief Scientific Officer
• Member of the Executive Management Team
• Chief Scientific Officer and Chair of Scientific Advisory Board
• Chief Scientific Officer Chair of Scientific Advisory Board

Dr. Chaturvedi has served as our Chief Scientific Officer in addition to continuing his responsibilities as the Chair of the company's Scientific Advisory Board (SAB) since March 1, 2022. He joined the Company in May 2017 as Chair of the SAB of Jaguar and Napo. Over his 30+ year career in the pharmaceutical industry, Dr. Chaturvedi has participated in the successful development and commercialization of multiple drugs in the therapeutic areas of epilepsy, HIV, hepatitis C, memory, and gastrointestinal disorders. Dr. Chaturvedi served as the President and Chief Scientific Officer of Napo from 2006 to 2013 and remained a scientific adviser of Napo from 2013 through 2017. Dr. Chaturvedi has co-founded and led multiple biotech enterprises. From 2001 through 2004, he served as the President, Chief Executive Officer, and Director of Scion Pharmaceuticals, Inc. He is the founder of IndUS Pharmaceuticals, where he has served as Chairman and Director since 2017, and held the same roles from 2005 through 2007 and from 2010 through 2015. IndUS Pharmaceuticals merged with Pivot Pharmaceuticals in 2015 and Dr. Chaturvedi served as the President and CEO of Pivot Pharmaceuticals from 2015 to 2017, prior to assuming his role as the Chair of the SAB for Napo and Jaguar. Dr. Chaturvedi also co-founded Oceanyx Pharmaceuticals, where he has served as Chief Executive Officer and Director since 2011, and he continues to serve on the boards of IndUS, Oceanyx, Enlivity, and Cellanyx. He has been an adjunct faculty member at Georgetown University since 2013. Earlier in his career, from 1994 through 2001, Dr. Chaturvedi served in various roles as the head of lead evaluation at Vertex Pharmaceuticals, and from 1993 through 1994 he was in the preclinical group at Alkermes Inc. He started his career in the product development group at Parke-Davis/Warner-Lambert Company (now Pfizer) in 1988, where he worked through 1993. Dr. Chaturvedi holds a PhD in Pharmaceutical Sciences from West Virginia University and a Bachelor's in Pharmacy from the University of Bombay.

Job Titles:

• Member of the Executive Management Team
• Chief Sustainable Supply, Ethnobotanical Research, and IP Officer
• Head of Sustainable Supply

Dr. King has served as our head of sustainable supply, ethnobotanical research, and intellectual property since 2004. Prior to that, he served as the Vice President of Ethnobotany and Conservation at Shaman Pharmaceuticals, Inc. Dr. King has been recognized by the International Natural Products and Conservation Community for the creation and dissemination of research on the long-term sustainable harvest and management of Croton lechleri, the widespread source of crofelemer. Dr. King is currently a member of the board of directors of Healing Forest Conservatory, a California not-for-profit public benefit corporation. Dr. King holds an MS and PhD in biology from the City University of New York (CUNY), and he received the first doctoral fellowship granted by the Institute of Economic Botany of the New York Botanical Garden.